基质金属蛋白酶及基质金属蛋白酶抑制剂在慢性鼻窦炎中的影响

doi:10.3760/cma.j.cn441417-20241205-08005

摘要/Abstract

摘要：

慢性鼻窦炎是一种鼻腔和鼻窦黏膜的慢性炎症，根据其临床表现分为慢性鼻窦炎不伴鼻息肉（chronic sinusitis without nasal polyps，CRSsNP）和慢性鼻窦炎伴鼻息肉（chronic sinusitis with nasal polyps，CRSwNP），目前保守治疗效果欠佳，且术后复发率较高，极大地影响了患者的生活质量。慢性鼻窦炎的发病机制可能与鼻腔黏膜上皮破坏、组织重塑、细菌感染等因素有关。有大量研究表明，组织重塑在慢性鼻窦炎的发生发展过程中起至关重要作用。细胞外基质（extracellular matrix，ECM）的异常降解是组织重塑的一部分，其中基质金属蛋白酶（matrix metalloproteinase，MMPs）和基质金属蛋白酶抑制剂（matrix-metalloproteinase inhibitor，TIMPs）是调控ECM代谢的关键因子。因此，本文就MMPs和TIMPs对慢性鼻窦炎的影响进行综述。

关键词:

慢性鼻窦炎, 鼻息肉, 基质金属蛋白酶, 基质金属蛋白酶抑制剂, 组织重塑, 综述

Abstract:

Chronic sinusitis (CRS) is a chronic inflammation of nasal cavity and sinus mucosa. According to its clinical manifestations, it can be divided into chronic sinusitis without nasal polyps (CRSsNP) and chronic sinusitis with nasal polyps (CRSwNP). The current conservative treatment effect is not good, and the postoperative recurrence rate is high, which greatly affects the patients' quality of life. The pathogenesis of CRS may be related to the destruction of nasal mucosa epithelium, tissue remodeling, bacterial infection, and other factors. At present, studies show that tissue remodeling plays an important role in the occurrence and development of CRS. Abnormal degradation of extracellular matrix (ECM) is a part of tissue remodeling, in which matrix metalloproteinases (MMPs) and matrix metalloproteinase inhibitors (TIMPs) are the key factors regulating ECM metabolism. Therefore, this paper summarizes the influence of MMPs and TIMPs on CRS.

Key words:

Chronic sinusitis；Nasal polyp；Matrix metalloproteinases；Matrix metalloproteinase inhibitors；Tissue remodeling, Review

苗森皓李秀国.

基质金属蛋白酶及基质金属蛋白酶抑制剂在慢性鼻窦炎中的影响 [J]. 国际医药卫生导报, 2025, 31(8): 1254-1257.

Miao Senhao, Li Xiuguo.

Effects of matrix metalloproteinases and matrix metalloproteinase inhibitors on chronic sinusitis [J]. International Medicine and Health Guidance News, 2025, 31(8): 1254-1257.

参考文献

[1] Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery; Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of chronic rhinosinusitis (2018)[J]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2019,54(2):81-100. DOI: 10.3760/cma.j.issn.1673-0860.2019.02.001.
[2] Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators[J]. Allergy, 2006,61(11):1280-1289. DOI: 10.1111/j.1398-9995.2006.01225.x.
[3] Shi LL, Liu Z. Corrigendum for "Features of airway remodeling in different types of Chinese chronic rhinosinusitis are associated with inflammation patterns"[J]. Allergy, 2022,77(8):2576-2577. DOI: 10.1111/all.15335
[4] Staudacher AG, Peters AT, Kato A, et al. Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis[J]. Ann Allergy Asthma Immunol, 2020,124(4):318-325. DOI: 10.1016/j.anai.2020.01.013.
[5] Amirapu S, Biswas K, Radcliff FJ, et al. Sinonasal tissue remodelling during chronic rhinosinusitis[J]. Int J Otolaryngol, 2021,2021:7428955. DOI: 10.1155/2021/7428955.
[6] Ingber DE, Dike L, Hansen L, et al. Cellular tensegrity: exploring how mechanical changes in the cytoskeleton regulate cell growth, migration, and tissue pattern during morphogenesis[J]. Int Rev Cytol, 1994,150:173-224. DOI: 10.1016/s0074-7696(08)61542-9.
[7] Malinsky RR, Valera FCP, Fransérgio Emílio Cavallari,et al.Matrix metalloproteinases and their impact on sinusal extension in chronic rhinosinusitis with nasal polyps[J]. Eur Arch Otorhinolaryngol, 2013, 270(4):1345-1348.DOI:10.1007/s00405-012-2219-9.
[8] Lin PK, Davis GE. Extracellular matrix remodeling in vascular disease: defining its regulators and pathological influence[J]. Arterioscler Thromb Vasc Biol, 2023,43(9):1599-1616. DOI: 10.1161/ATVBAHA.123.318237.
[9] Vilardi A, Przyborski S, Mobbs C, et al. Current understanding of the interplay between extracellular matrix remodelling and gut permeability in health and disease[J]. Cell Death Discov, 2024,10(1):258. DOI: 10.1038/s41420-024-02015-1.
[10] 刘明明,李爱玲,修瑞娟. 基质金属蛋白酶的研究进展[J]. 中国病理生理杂志,2018,34(10):1914-1920. DOI:10.3969/j.issn.1000-4718.2018.10.029.
[11] Roy R, Morad G, Jedinak A, et al. Metalloproteinases and their roles in human cancer[J]. Anat Rec (Hoboken), 2020, 303(6):1557-1572. DOI: 10.1002/ar.24188.
[12] Patterson ML, Atkinson SJ, Knäuper V, et al. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain[J]. FEBS Lett, 2001,503(2-3):158-62. DOI: 10.1016/s0014-5793(01)02723-5.
[13] Murphy G, Nguyen Q, Cockett MI, et al. Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant[J]. J Biol Chem, 1994,269(9):6632-6636.
[14] Houghton AM. Matrix metalloproteinases in destructive lung disease[J]. Matrix Biol, 2015,44-46:167-174. DOI: 10.1016/j.matbio.2015.02.002.
[15] Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells[J]. Biochim Biophys Acta, 2005,1755(1):37-69. DOI: 10.1016/j.bbcan.2005.03.001.
[16] Can IH, Ceylan K, Caydere M, et al. The expression of MMP-2, MMP-7, MMP-9, and TIMP-1 in chronic rhinosinusitis and nasal polyposis[J]. Otolaryngol Head Neck Surg, 2008,139(2):211-215. DOI: 10.1016/j.otohns.2008.04.032.
[17] Buisson AC, Zahm JM, Polette M, et al. Gelatinase B is involved in the in vitro wound repair of human respiratory epithelium[J]. J Cell Physiol, 1996,166(2):413-426. DOI: 10.1002/(SICI)1097-4652(199602)166:2<413::AID-JCP20>3.0.CO;2-A.
[18] Chen YS, Langhammer T, Westhofen M, et al. Relationship between matrix metalloproteinases MMP-2, MMP-9, tissue inhibitor of matrix metalloproteinases-1 and IL-5, IL-8 in nasal polyps[J]. Allergy, 2007,62(1):66-72. DOI: 10.1111/j.1398-9995.2006.01255.x.
[19] Sehmi R. Role of interleukin 33 in chronic rhinosinusitis[J]. Thorax, 2017,72(7):591-593. DOI: 10.1136/thoraxjnl-2016-209655.
[20] Watelet JB, Bachert C, Claeys C, et al. Matrix metalloproteinases MMP-7, MMP-9 and their tissue inhibitor TIMP-1: expression in chronic sinusitis vs nasal polyposis[J]. Allergy, 2004,59(1):54-60. DOI: 10.1046/j.1398-9995.2003.00364.x.
[21] Chen G, Ge D, Zhu B, et al. Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios may be involved in lipopolysaccharide-induced acute lung injury[J]. J Int Med Res, 2020,48(4):300060520919592. DOI: 10.1177/0300060520919592.
[22] Guerra G, Testa D, Salzano FA, et al. Expression of matrix metalloproteinases and their tissue inhibitors in chronic rhinosinusitis with nasal polyps: etiopathogenesis and recurrence[J]. Ear Nose Throat J, 2021,100(5_suppl):597S-605S. DOI: 10.1177/0145561319896635.
[23] Cao W, Liu Y, Chen Y.miR-134 up-regulates matrix metalloproteinase 9 (MMP9) in chronic sinusitis[J]. J Biomater Tissue Eng, 2023,13(1):94-98.DOI:10.1166/jbt.2023.3206.
[24] Watelet JB, Claeys C, Van Cauwenberge P, et al. Predictive and monitoring value of matrix metalloproteinase-9 for healing quality after sinus surgery[J]. Wound Repair Regen, 2004,12(4):412-418. DOI: 10.1111/j.1067-1927.2004.012411.x.
[25] Lees KA, Orlandi RR, Oakley G, et al. The role of macrolides and doxycycline in chronic rhinosinusitis[J]. Immunol Allergy Clin North Am, 2020,40(2):303-315. DOI: 10.1016/j.iac.2019.12.005.
[26] Verma SP, Das P. Monensin induces cell death by autophagy and inhibits matrix metalloproteinase 7 (MMP7) in UOK146 renal cell carcinoma cell line[J]. In Vitro Cell Dev Biol Anim, 2018,54(10):736-742. DOI: 10.1007/s11626-018-0298-7.
[27] Liao HY, Da CM, Liao B, et al. Roles of matrix metalloproteinase-7 (MMP-7) in cancer[J]. Clin Biochem, 2021,92:9-18. DOI: 10.1016/j.clinbiochem.2021.03.003.
[28] Van Doren SR. MMP-7 marks severe pancreatic cancer and alters tumor cell signaling by proteolytic release of ectodomains[J]. Biochem Soc Trans, 2022,50(2):839-851. DOI: 10.1042/BST20210640.
[29] Chen X, Chang L, Li X, et al. Tc17/IL-17A up-regulated the expression of MMP-9 via NF-κB pathway in nasal epithelial cells of patients with chronic rhinosinusitis[J]. Front Immunol, 2018,9:2121. DOI: 10.3389/fimmu.2018.02121.
[30] Li X, Meng J, Qiao X, et al. Expression of TGF, matrix metalloproteinases, and tissue inhibitors in Chinese chronic rhinosinusitis[J]. J Allergy Clin Immunol, 2010,125(5):1061-1068. DOI: 10.1016/j.jaci.2010.02.023.
[31] Can IH, Ceylan K, Caydere M, et al. The expression of MMP-2, MMP-7, MMP-9, and TIMP-1 in chronic rhinosinusitis and nasal polyposis[J]. Otolaryngol Head Neck Surg, 2008,139(2):211-215. DOI: 10.1016/j.otohns.2008.04.032.
[32] Wang X, Khalil RA. Matrix Metalloproteinases, vascular remodeling, and vascular disease[J]. Adv Pharmacol, 2018,81:241-330. DOI: 10.1016/bs.apha.2017.08.002.
[33] 张亮. 组织重塑相关因子在慢性鼻窦炎中表达[C]//全国免疫学学术大会.合肥, 2016:550-551.
[34] Lou H, Meng Y, Piao Y, et al. Predictive significance of tissue eosinophilia for nasal polyp recurrence in the Chinese population[J]. Am J Rhinol Allergy, 2015,29(5):350-356. DOI: 10.2500/ajra.2015.29.4231.